Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.

Study:

Paclitaxel Poliglumex (CT-2103) vs. Paclitaxel for the Treatment of Women With Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer (NSCLC) Who Are Performance Status 2.

Rationale:

n/a

Purpose:

This is a randomized, open-label, multinational, phase III study in women with histologically- or cytologically-confirmed advanced NSCLC who are chemotherapy naïve and have PS 2. Study drug will be administered on day 1 of each 21 day cycle

Study Status: Terminated

Recruiting:
n/a

Condition Intervention Phase
NSCLC Drug: paclitaxel
Drug: paclitaxel poliglumex		 Phase 3

Verified by Cell Therapeutics February, 2007

Sponsored by: Cell Therapeutics
Information provided by: Cell Therapeutics
ClinicalTrials.gov identifier: NCT00269828

Study Type: Interventional

Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study

The Cleveland Clinic Foundation, Taussig Cancer Center
Cleveland, Ohio 44195
United States

n/a

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.